| Budget Amount *help |
¥3,800,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥300,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2006: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2005: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Research Abstract |
In chronic hepatitis C, the interindividual difference in responses against the hepatic necroinflammation appears to be important in the progression of liver fibrosis. This study was to examine the possible association of MMP-1 -1607 1G/2G, MMP-2. -1306 C/T, MMP-3 -1171 5A/6A, MMP-7 -181 A/G, MMP-9 -1562 T/C, TGF-βl +819 T/C, IL-lβ -511 C/T, IL-1RN VNTR polymorphisms with the progression of liver fibrosis in Japanese patients with hepatitis C virus-related chronic liver disease, using cross-sectional and longitudinal study designs. We examined 93 chronic hepatitis C patients and 90 liver cirrhosis C patients. The chronic hepatitis patients were divided into progressive fibrosis and non-progressive fibrosis groups. Gene lymorphisms were analyzed using a polymerase-chain reaction-based assay. In the cross-sectional study, the MMP-1 2G/2G homozygotes and MMP-9 C/C homozygotes were significantly more in cirrhosis group than in chronic hepatitis group, whereas other genotypes showed no significant differences. In the longitudinal study, MMP-3 5A carriers and TGF-β1 T carriers were significantly more in the progressive fibrosis group than in non-progressive fibrosis group, whereas other genotypes showed no significant differences. These findings suggest that MMP-1, MMP-3, MMP-9 and TGF-131 genotypes account for some of the variability in the progression of chronic hepatitis C.
|
